Cargando…

Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide

SIMPLE SUMMARY: Previous studies have reported an association between the ratio of neutrophils to lymphocytes circulating in blood and outcomes in patients with cancer. This study examined the association between lymphocyte and neutrophil counts and survival in a prospective trial of preoperative ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skubitz, Keith M., Domingo-Musibay, Evidio, Lindgren, Bruce R., Cheng, Edward Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316699/ https://www.ncbi.nlm.nih.gov/pubmed/35884480 http://dx.doi.org/10.3390/cancers14143419

Ejemplares similares

Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide
por: Skubitz, Keith M, et al.
Publicado: (2022)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas
por: Buonadonna, Angela, et al.
Publicado: (2023)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
por: Coldiron, Matthew E., et al.
Publicado: (2021)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Sequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule
por: Almeida, G. F. G., et al.
Publicado: (2011)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
por: Jones, Robin L., et al.
Publicado: (2021)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients
por: URAKAWA, HIROSHI, et al.
Publicado: (2014)

Doxorubicin and ifosfamide for recurrent renal synovial sarcoma: The first case report in Indonesia
por: Fitra, Ahmad Fathira, et al.
Publicado: (2022)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
por: Bafaloukos, D, et al.
Publicado: (2004)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide
por: Chawla, Sant P, et al.
Publicado: (2013)

Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
por: Miller, Devon, et al.
Publicado: (2022)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females
por: Zanetta, G, et al.
Publicado: (1999)

A Case of Renal Synovial Sarcoma: Complete Remission was Induced by Chemotherapy with Doxorubicin and Ifosfamide.
por: Park, Soo-Jin, et al.
Publicado: (2004)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304
por: Tanaka, Kazuhiro, et al.
Publicado: (2019)

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
por: Leyvraz, S, et al.
Publicado: (2006)

Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

A Case of Retroperitoneal Synovial Sarcoma in Pregnancy Treated with Antepartum Doxorubicin plus Ifosfamide Chemotherapy
por: Sipe, Bradley H., et al.
Publicado: (2021)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
por: Guest, Julian F., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tfoh5sdlpriikpmu4v6oigvl8g